KEVIN BUNKER, PhD, CHIEF SCIENTIFIC OFFICER
Dr. Bunker is a founder, Board member, and the CSO of Kalyra Pharmaceuticals. He developed the core technology around which Kalyra was founded. Prior to founding Kalyra, Dr. Bunker was an award-winning scientist in Pfizer’s drug discovery research group in La Jolla, as part of the medicinal chemistry department. During his time at Pfizer, he worked on multiple therapeutic areas including oncology, diabetes, antivirals, and ophthalmology, and received several awards for his contributions. Prior to Pfizer, Dr. Bunker carried out postdoctoral research at The Scripps Research Institute under the direction of Professor Dale Boger. He received his PhD in organic chemistry from the University of California, San Diego under the direction of Joseph O’Connor. He is the inventor on multiple patents and an author of multiple articles in peer-reviewed journals.
CAM GALLAGHER, CHIEF BUSINESS OFFICER
Mr. Gallagher is the Chief Business Officer for Kalyra and currently also serves as the sole Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2007. He is a Director at Retrosense Therapeutics, a privately held gene therapy company focused on optogenetics for late stage patients with retinitis pigmentosa. He has served as Chairman of the Board of Directors of DioGenix, Inc., a privately held molecular diagnostic company in Gaithersburg, Maryland. Mr. Gallagher was a Director at Sorrento Therapeutics, a publicly held monoclonal antibody company with a focus on oncology from 2012 to 2014. From December 2004 through June 2007, Mr. Gallagher served in various senior marketing positions of increasing responsibility at Verus Pharmaceuticals, Inc., a privately held specialty pharmaceutical company in San Diego, California. Prior to his role at Verus Pharmaceuticals he held positions of increasing management responsibilities at CV Therapeutics and Dura Pharmaceuticals. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.S. in Business Administration from the Ohio University.
DEBORAH SLEE, PhD, SENIOR VICE PRESIDENT of RESEARCH & DEVELOPMENT
Dr. Slee has over 20 years experience in R & D for major biotech and pharmaceutical companies, as well as start-ups. She brings expertise in facilitating preclinical development and clinical translation of novel therapeutics, particularly in start-up environments. She was previously the V. P. of R & D at EnduRx Pharmaceuticals and Convoy Therapeutics, and in 2010 she co-founded Aspyrian Therapeutics and CendR Therapeutics. Prior to this, she was a Director of Medicinal Chemistry and program leader at Neurocrine Biosciences, and held positions of increasing responsibility at Ontogen Corporation. Dr. Slee completed her post-doctoral research ad the Scripps Research Institute, earned her PhD from the University of Exeter and her Bachelors degree from the University of Hertfordshire in the U.K. Before completing her PhD, she worked at Glaxo Group Research and Unilever Research.